The primary goal of this joint venture is to develop and commercialise novel cell therapy products for major unmet medical needs in the United States, Japan, and EU regions
Comprehensive clinical development programs being initiated for each investigational candidate
The clearance of this audit marks the successful registration of 8 APIs with CADIFA
This PAI-cum-GMP USFDA inspection was conducted from December 14 to December 22, 2023
Atlas Life Sciences (India) has successfully commenced the commercial production of API - Intermediate at its new plant at Chhatral,
The findings of Phase 3 study are in line with Phase 2 study conducted in the US and Europe
First published clinical trial using live biotherapeutic candidate in Covid-19 patients suggests role in improving outcomes
Blenrep (belantamab mafodotin) plus BorDex showed statistically significant progression-free survival (PFS) benefit versus daratumumab plus BorDex
Gene therapy AB-1005 being developed to locally increase glial cell line-derived neurotrophic factor (GDNF) levels
This approval showcases Teva’s proven strengths in complex generic formulations development and device engineering
Subscribe To Our Newsletter & Stay Updated
